198 related articles for article (PubMed ID: 24117400)
21. A slow, tight-binding inhibitor of the zinc-dependent deacetylase LpxC of lipid A biosynthesis with antibiotic activity comparable to ciprofloxacin.
McClerren AL; Endsley S; Bowman JL; Andersen NH; Guan Z; Rudolph J; Raetz CR
Biochemistry; 2005 Dec; 44(50):16574-83. PubMed ID: 16342948
[TBL] [Abstract][Full Text] [Related]
22. Assignment of 1H, 13C and 15N backbone resonances of Escherichia coli LpxC bound to L-161,240.
Barb AW; Jiang L; Raetz CR; Zhou P
Biomol NMR Assign; 2010 Apr; 4(1):37-40. PubMed ID: 19941092
[TBL] [Abstract][Full Text] [Related]
23. Structure of the LpxC deacetylase with a bound substrate-analog inhibitor.
Coggins BE; Li X; McClerren AL; Hindsgaul O; Raetz CR; Zhou P
Nat Struct Biol; 2003 Aug; 10(8):645-51. PubMed ID: 12833153
[TBL] [Abstract][Full Text] [Related]
24. Molecular recognition by Escherichia coli UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase is modulated by bound metal ions.
Hernick M; Fierke CA
Biochemistry; 2006 Dec; 45(49):14573-81. PubMed ID: 17144651
[TBL] [Abstract][Full Text] [Related]
25. LpxC inhibitors as new antibacterial agents and tools for studying regulation of lipid A biosynthesis in Gram-negative pathogens.
Tomaras AP; McPherson CJ; Kuhn M; Carifa A; Mullins L; George D; Desbonnet C; Eidem TM; Montgomery JI; Brown MF; Reilly U; Miller AA; O'Donnell JP
mBio; 2014 Sep; 5(5):e01551-14. PubMed ID: 25271285
[TBL] [Abstract][Full Text] [Related]
26. High-throughput catch-and-release synthesis of oxazoline hydroxamates. Structure-activity relationships in novel inhibitors of Escherichia coli LpxC: in vitro enzyme inhibition and antibacterial properties.
Pirrung MC; Tumey LN; McClerren AL; Raetz CR
J Am Chem Soc; 2003 Feb; 125(6):1575-86. PubMed ID: 12568618
[TBL] [Abstract][Full Text] [Related]
27. 3D-QSAR, Molecular Docking and Molecular Dynamics Simulation of Pseudomonas aeruginosa LpxC Inhibitors.
Zuo K; Liang L; Du W; Sun X; Liu W; Gou X; Wan H; Hu J
Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28481250
[TBL] [Abstract][Full Text] [Related]
28. Mechanism and inhibition of LpxC: an essential zinc-dependent deacetylase of bacterial lipid A synthesis.
Barb AW; Zhou P
Curr Pharm Biotechnol; 2008 Feb; 9(1):9-15. PubMed ID: 18289052
[TBL] [Abstract][Full Text] [Related]
29. Proline-based hydroxamates targeting the zinc-dependent deacetylase LpxC: Synthesis, antibacterial properties, and docking studies.
Kalinin DV; Agoglitta O; Van de Vyver H; Melesina J; Wagner S; Riemann B; Schäfers M; Sippl W; Löffler B; Holl R
Bioorg Med Chem; 2019 May; 27(10):1997-2018. PubMed ID: 30954331
[TBL] [Abstract][Full Text] [Related]
30. UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase of Escherichia coli is a zinc metalloenzyme.
Jackman JE; Raetz CR; Fierke CA
Biochemistry; 1999 Feb; 38(6):1902-11. PubMed ID: 10026271
[TBL] [Abstract][Full Text] [Related]
31. Antibacterial Drug Discovery Targeting the Lipopolysaccharide Biosynthetic Enzyme LpxC.
Erwin AL
Cold Spring Harb Perspect Med; 2016 Jul; 6(7):. PubMed ID: 27235477
[TBL] [Abstract][Full Text] [Related]
32. Structure of the bacterial deacetylase LpxC bound to the nucleotide reaction product reveals mechanisms of oxyanion stabilization and proton transfer.
Clayton GM; Klein DJ; Rickert KW; Patel SB; Kornienko M; Zugay-Murphy J; Reid JC; Tummala S; Sharma S; Singh SB; Miesel L; Lumb KJ; Soisson SM
J Biol Chem; 2013 Nov; 288(47):34073-34080. PubMed ID: 24108127
[TBL] [Abstract][Full Text] [Related]
33. UDP-3-O-((R)-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase functions through a general acid-base catalyst pair mechanism.
Hernick M; Gennadios HA; Whittington DA; Rusche KM; Christianson DW; Fierke CA
J Biol Chem; 2005 Apr; 280(17):16969-78. PubMed ID: 15705580
[TBL] [Abstract][Full Text] [Related]
34. Uridine-based inhibitors as new leads for antibiotics targeting Escherichia coli LpxC.
Barb AW; Leavy TM; Robins LI; Guan Z; Six DA; Zhou P; Hangauer MJ; Bertozzi CR; Raetz CR
Biochemistry; 2009 Apr; 48(14):3068-77. PubMed ID: 19256534
[TBL] [Abstract][Full Text] [Related]
35. Structure-based discovery of LpxC inhibitors.
Zhang J; Chan A; Lippa B; Cross JB; Liu C; Yin N; Romero JA; Lawrence J; Heney R; Herradura P; Goss J; Clark C; Abel C; Zhang Y; Poutsiaka KM; Epie F; Conrad M; Mahamoon A; Nguyen K; Chavan A; Clark E; Li TC; Cheng RK; Wood M; Andersen OA; Brooks M; Kwong J; Barker J; Parr IB; Gu Y; Ryan MD; Coleman S; Metcalf CA
Bioorg Med Chem Lett; 2017 Apr; 27(8):1670-1680. PubMed ID: 28302397
[TBL] [Abstract][Full Text] [Related]
36. Design, synthesis and structure-activity relationship evaluation of novel LpxC inhibitors as Gram-negative antibacterial agents.
Ding S; Dai RY; Wang WK; Cao Q; Lan LF; Zhou XL; Yang YS
Bioorg Med Chem Lett; 2018 Jan; 28(2):94-102. PubMed ID: 29233653
[TBL] [Abstract][Full Text] [Related]
37. LpxC inhibition: Potential and opportunities with carbohydrate scaffolds.
Amudala S; Sumit ; Aidhen IS
Carbohydr Res; 2024 Mar; 537():109057. PubMed ID: 38402732
[TBL] [Abstract][Full Text] [Related]
38. Mechanistic inferences from the binding of ligands to LpxC, a metal-dependent deacetylase.
Gennadios HA; Whittington DA; Li X; Fierke CA; Christianson DW
Biochemistry; 2006 Jul; 45(26):7940-8. PubMed ID: 16800620
[TBL] [Abstract][Full Text] [Related]
39. Escherichia coli versus Pseudomonas aeruginosa deacetylase LpxC inhibitors selectivity: surface and cavity-depth-based analysis.
Kadam RU; Shivange AV; Roy N
J Chem Inf Model; 2007; 47(3):1215-24. PubMed ID: 17441707
[TBL] [Abstract][Full Text] [Related]
40. Crystal structure of LpxC, a zinc-dependent deacetylase essential for endotoxin biosynthesis.
Whittington DA; Rusche KM; Shin H; Fierke CA; Christianson DW
Proc Natl Acad Sci U S A; 2003 Jul; 100(14):8146-50. PubMed ID: 12819349
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
